It is well established that inhibition of P-gp function can limit ceramide glycosylation, and because the inhibitor regimen demonstrated efficacy in drug-resistant, P-gp-expressing AML models, we sought to assess the role of P-gp in this process. The gene discussed is PGP; the disease is acute myeloid leukemia.